RENLANE™ Renal Denervation System from Cordis Gets CE Mark

Even while panels and journals continue to debate the efficacy of renal denervation in treating resistent hypertension, a situation brought to the forefront by Medtronic's announcement in January that its pivotal U.S. renal denervation trial failed to meet its pre-specified endpoint, the Conformité Européenne has bestowed its CE Mark on a brand new system from Cordis Corporation.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news